Med24
Clinical Medicine 19. 10. 2026 • 2 min read • MedPage Today

'Groundbreaking Option' Approved for Rectal Cancer

The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. The approval allows use in stage II/III patients with...

'Groundbreaking Option' Approved for Rectal Cancer

The Food and Drug Administration granted accelerated approval to dostarlimab for use in select patients with operable rectal cancer. This approval applies to stage II/III patients identified with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) rectal cancer, representing approximately 3% of locally advanced cases. Patients achieving a complete response may potentially avoid standard treatment, which typically includes chemotherapy, radiation, and surgery. Support for this approval stems from the AZUR-1 trial.

The AZUR-1 trial demonstrated that the majority of patients with dMMR/MSI-H rectal cancers and other solid tumors treated with dostarlimab achieved a complete response and were able to avoid surgery. Principal investigator Andrea Cercek noted the potential for neoadjuvant PD-1 inhibition to eradicate the need for traditional therapies in a subset of patients. An exploratory analysis of AZUR-1 showed that 76% of evaluable patients had no evidence of cancer a year or more after treatment, with no recurrences reported after more than 2 years of follow-up.

Sponsored content

Adverse events observed in the AZUR-1 trial included fatigue, rash, diarrhea, and pruritus. Grade 3 adverse events included diabetes, lung infection, hypothyroidism, encephalitis, and neutropenia. The labeling notes the potential for immune-mediated adverse events. Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial. Dostarlimab has multiple approved indications in endometrial cancer and is approved for previously treated dMMR recurrent or advanced solid tumors.

Original Scientific Source
MedPage Today
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement